Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folium ginkgo extract + tetramethylpyrazine sodium chloride
- Development stage
- Phase 4
- Lead developer
- Honghe Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Folium Ginkgo Extract + Tetramethylpyrazine Sodium Chloride Injection, marketed under the brand name Xingxiong Injection (or Mainuokang), is a traditional Chinese medicine (TCM)-derived compound preparation approved and used in China for the treatment of ischemic stroke, cerebral ischemia/reperfusion injury, and coronary heart disease. It is a fixed-dose combination containing two active components: an extract from Folium Ginkgo (Ginkgo biloba leaves) and tetramethylpyrazine sodium chloride (a derivative of ligustrazine, an alkaloid originally isolated from Ligusticum chuanxiong). The drug is administered by intravenous injection and works through multiple biological targets, including antagonism of the platelet-activating factor receptor (PAFR) and blockade of L-type calcium channels. This multi-target mechanism leads to downstream activation of the Akt/Nrf2 signaling pathway and inhibition of the NLRP3 inflammasome, thereby reducing neuroinflammation, oxidative stress, and apoptosis in ischemic brain tissue.
- Brand names
- Mainuokang迈诺康
- Other names
- Xingxiong InjectionXingxiong Sodium Chloride Injectionfloium ginkgo extract + tetramethylpyrazine sodium chloridefolium ginkgo extract and tetramethylpyrazine sodium chloride injection杏芎注射液杏芎氯化钠注射液
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AMPK (Adenosine monophosphate–activated protein kinase)LTCC (Voltage-gated calcium channel (L-type))NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)P2Y12 (Purinergic P2Y12 receptor)PTAFR (Platelet-activating factor receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on folium ginkgo extract + tetramethylpyrazine sodium chloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folium ginkgo extract + tetramethylpyrazine sodium chloride.